MicroSectors FANG and Innovation 3X Leveraged ETN vs SELLAS Life Sciences Group Inc. Common Stock — how do they compare? MicroSectors FANG and Innovation 3X Leveraged ETN trades at $36.84 (market cap $2.92B), while SELLAS Life Sciences Group Inc. Common Stock trades at $11.27 (market cap $2.28B). The key difference: MicroSectors FANG and Innovation 3X Leveraged ETN is the larger of the two by market cap, and MicroSectors FANG and Innovation 3X Leveraged ETN is trading nearer its 52-week high, SELLAS Life Sciences Group Inc. Common Stock nearer its low. Which is the better fit depends on your goals.
| FNGU | SLS | |
|---|---|---|
Market Cap | $2.92B | $2.28B |
Volume | 1,949,737 | 3,128,960 |
Sector | Leveraged / Inverse | Health |
52-Week High | $37.20 | $15.46 |
52-Week Low | $13.73 | $1.39 |
Typical Hold Time | 19 Days | — |
Enterprise Value | — | $2.15B |
Signals from Pluang's Aura AI — not financial advice
FNGU, a triple-leveraged ETN tracking major tech stocks, trades at $37.2, up 1.92% today with a bullish technical signal from moving averages. Support and resistance levels are tightly clustered near the current price, while oscillators show neutral to overbought conditions. The ETN provides amplified exposure to tech giants but carries inherent leverage risks.
The outlook hinges on the performance of underlying tech holdings; recent news highlights historical volatility, with an 87% loss during past sector downturns. Investors face significant upside potential from tech growth but must weigh extreme volatility and leverage decay risks inherent in the product structure.
No Aura AI signal available yet.
Trailing returns across standard periods
FNGU is a leveraged ETN that seeks to provide three times (3x) the daily performance of top tech and innovation stocks. It is intended for traders seeking magnified short-term returns.
Read more on FNGU →SELLAS Life Sciences is a late-stage clinical biopharmaceutical company developing therapies for cancer. Its programs include a WT1-targeting cancer immunotherapy and a selective CDK9 inhibitor.
Read more on SLS →